Following publication of research findings in the journal Science Translational Medicine, Patrik Brundin, MD, PhD, director of Van Andel Research Institute’s Center for Neurodegenerative Science, and chairman of The Cure Parkinson’s Trust’s Linked Clinical Trials Committee, discusses MSDC-0160, a new investigational drug originally developed for type 2 diabetes that is being readied for human clinical trials in search of the world’s first treatment to impede the progression of Parkinson’s disease.
Credit: Video courtesy of the Patrik Brundin Laboratory, Van Andel Research Institute.
$245 billion is spent annually to treat type 2 diabetes in the U.S. Globally, nearly 50 percent of those diagnosed with diabetes live in just 3 countries (China, India, U.S.). Yet, diabetes can and should be prevented.
Alzheimer’s disease has been characterized as “type 3 diabetes.” Insulin sensitizers may play a role in treating Alzheimer’s disease and MSDC has developed a new insulin sensitizer that may prevent cognitive decline in people with Alzheimer’s-related dementia.
Data presented to date suggest that the mTOT protein complex functions as a molecular "sensor switch" connecting mitochondrial metabolism to important cellular activities perturbed in age-related metabolic diseases such as type 2 diabetes, including insulin sensitivity. MSDC's novel pharmaceutical agents selectively bind and modulate proteins in the mTOT complex, effecting pyruvate utilization and resulting in improved insulin action, lipid oxidation, preservation of beta cell function, and generation of brown fat.
Type 2 diabetes is a metabolic disorder affecting the ways in which the body uses various nutrients for growth and energy. The root cause of this disorder is insulin resistance, which is a result of the body's inability to efficiently and effectively convert glucose - a simple sugar made from the food you eat - to energy. Insulin, a hormone produced by the beta cells in the pancreas, aids in the transfer of glucose into the bloodstream, where it is used or metabolized by cells for growth and energy. Diabetes results when changes in metabolism alter both the ability of insulin to work on its target tissues and the ability of the beta cells to make and secrete insulin.
"Our goal is to develop drugs that will have positive effects on healthcare outcomes."
A mitochondrial protein complex has been identified by researchers at Metabolic Solutions Development Company (MSDC) through which anti-diabetic drugs exert their insulin sensitizing effects when used to treat patients diagnosed with type 2 diabetes. The mitochondrial protein complex is being referred to as the mitochondrial Target of Thiazolidinediones (TZDs), or mTOT™.
In a recently completed Phase 2b study, MSDC-0160, a novel once-a-day oral insulin sensitizer and a prototype first in a new class of therapeutic agents called mTOT Modulators™, which are being developed by researchers at Metabolic Solutions Development Company (MSDC), met the primary endpoint of significantly reducing fasting plasma glucose (FPG) in patients diagnosed with type 2 diabetes, and significantly reduced hemoglobin A1c (HbA1c).
New Research Suggests Novel Insulin Sensitizer Works Through a New Mechanism to Treat Root Cause of Type 2 Diabetes
Washington University School of Medicine researchers show MSDC compound has anti-diabetic efficacy without side effects profile of current drugs to treat insulin resistance
A study published online in the Journal of Biological Chemistry, titled “Insulin Resistance and Metabolic Derangements in Obese Mice are Ameliorated by a Novel Peroxisome Proliferator-Activated Receptor-sparing Thiazolidinedione”, showed a new drug to treat diabetes being developed by Metabolic Solutions Development Company (MSDC), MSDC-0602, improved insulin resistance and inflammation in obese mice. These findings suggest that MSDC-0602, a novel anti-diabetic drug which is in Phase 2 clinical trials, may constitute the first in a class of next generation insulin sensitizers that appear to work through a new biochemical mechanism to treat insulin resistance and type 2 diabetes.